Expression of complement receptors and regulatory proteins on alveolar CD4+ lymphocytes from human immunodeficiency virus-1 infected individuals


ABSTRACT: Several lines of evidence suggest a dysregulation of the complement system in human immunodeficiency virus-1 (HIV-1) infected patients. The aim of this study was to elucidate whether CD4+ alveolar lymphocytes from HIV-1 infected patients show a loss of complement regulatory proteins that would render these cells susceptible to antibody-dependent complement-mediated cytotoxicity.

We investigated the expression of complement regulatory (CD46, CD55, CD59) and complement receptor (CR1, CR2, CR3, CR4) proteins on alveolar cells by flow cytometry. Cells were obtained by bronchoalveolar lavage from 17 HIV-1 infected and 12 HIV-1 negative individuals. Expression of adhesion molecules (leucocyte functional associated antigen-1 (LFA-1), intercellular adhesion molecule-1 (ICAM-1)) and CD30 were evaluated in patient subgroups. In addition, interleukin (IL) Functional associated antigen-1 (LFA-1), intercellular adhesion molecule-1 (ICAM-1) and complement receptor (CR1, CR2, CR3, CR4) proteins on alveolar cells by flow cytometry. Cells were obtained by bronchoalveolar lavage from 17 HIV-1 infected and 12 HIV-1 negative individuals. Expression of adhesion molecules (leucocyte functional associated antigen-1 (LFA-1), intercellular adhesion molecule-1 (ICAM-1)) and CD30 were evaluated in patient subgroups. In addition, interleukin (IL)-1β, tumour necrosis factor alpha (TNF-α), IL-4 and interferon gamma (IFN-γ) concentrations were measured in supernatants of alveolar cells.

We found a significantly reduced expression of CD46 and CD59 on CD4+ alveolar lymphocytes from HIV-1 infected individuals, whereas the expression of CR3, CR4, ICAM-1 and CD30 was increased. IL-1β and TNF-α concentration in supernatants of alveolar cells was augmented in HIV-1 infected patients, but did not correlate with the expression of surface molecules. IFN-γ concentration was also increased and showed an inverse relationship to the surface expression of CD30.

Our data suggest that in human immunodeficiency virus-1 infection an increased level of activation is associated with a diminished expression of complement regulatory proteins on CD4+ alveolar lymphocytes. This phenomenon might contribute to the depletion of CD4+ lymphocytes and the local immunodeficiency in the pulmonary compartment.

and mortality of acquired immune deficiency syndrome (AIDS) patients. It has been postulated that the local immunodeficiency in the lung is due to a progressive decline of the pulmonary cytolytic capacity that is at least partly attributable to a depletion of CD4+ alveolar lymphocytes (ALs) [9].

The aim of this study was, therefore, to elucidate whether CD4+ ALs from HIV-1 infected individuals have lost protection by complement regulatory proteins, since this increases the susceptibility to ACC. As little is known about the regulation of the expression of complement regulatory and receptor proteins on T-cells, we examined the correlation between antigen expression, activation level as assessed by leucocyte functional associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) expression, cytokine production of alveolar cells (ACs) and CD30 status. CD30 is expressed on T-cells that produce predominantly type 2 T-helper (Th2) cytokines (i.e. interleukin (IL)-4, IL-10) rather than type 1 T-helper (Th1) cytokines (i.e. IL-2, interferon gamma (IFN-γ)) [10].

**Patients and methods**

**Patients**

We investigated the expression of complement regulatory proteins and complement receptors on CD4+ ALs and alveolar macrophages (AMs) obtained from 17 HIV-1 infected individuals (mean±SEM age 43±11 yrs; three female and 14 male; six smokers and 11 nonsmokers; one patient stage CDC I, three patients stage II and 13 patients stage III). The mean blood CD4 cell count was 134±133 cells·µL⁻¹. All but two patients were on current antiretroviral therapy. For comparison, seven healthy volunteers (mean age 25±3 yrs; all male; all nonsmokers) and five patients with suspected (n=2) or proven (n=3; all stage T1, squamous cell carcinomas) peripheral malignancy of the lung (mean age 58±7 yrs; all male; all smokers) were evaluated in the same manner by bronchoalveolar lavage (BAL). In HIV-1 infected patients, BAL was performed for exclusion (10 cases) or confirmation of opportunistic infections (seven patients; Mycobacterium tuberculosis (one), Cryptococcus neoformans (one), Pneumocystis carinii (two), other bacterial infections (three)).

**Bronchoalveolar lavage**

BAL was performed with a fibrescope (B71T20D; Olympus, Hamburg, Germany) placed in a wedge position in the middle lobe. Six to eight 20 mL aliquots of sterile saline were instilled and immediately aspirated.

Differential cell counts were performed after two washes in sterile saline solution and staining with Wright-Giemsa. BAL samples with more than 10% neutrophils were excluded.

**Flow cytometry (FACS)**

Four million cells were pre-incubated for 30 min with 20% bovine serum (Sigma, Deisenhofen, Germany) to block nonspecific binding. After centrifugation for 10 min at 400×g, cells were washed twice in phosphate buffered saline (PBS) solution. Cells were conveyed in suitably sized FACS tubes and 10 µL antibody was added. After 30 min incubation and two washes with PBS, two-colour flow cytometry (FACScan, Becton-Dickinson, Heidelberg, Germany) was performed using the following monoclonal antibodies: 1) Fluorescein conjugated: anti-CD4 (RPA-T4; Dianova, Hamburg, Germany); 2) R-phycocerythrin conjugated: anti-LFA-1 (C174/38; Biotrend, Köln, Germany), anti-CD3 (C135/44; Biotrend), anti-CD4 (3.9; Sigma, Deisenhofen, Germany), anti-CD2 (MON-1112R; CellSystem, Remagen, Germany), anti-CD30 (Ber-H2; Dako, Hamburg, Germany) and anti-ICAM-1 (C169/15.2; Biotrend); 3) Stained by secondary anti-mouse IgG R-phycocerythrin conjugated (27138, Dianova): anti-CR1 (J3D3; Dianova) and anti-CD46 (J4.48; Immunotech, Hamburg, Germany); and 4) Stained by secondary anti-mouse IgM R-phycocerythrin conjugated (SAM-2F; CellSystem): anti-CD55 (MON-1155; CellSystem) and anti-CD59 (MON-1156; CellSystem).

Fluorescein and R-phycocerythrin conjugated monoclonal antibodies anti-IGG1 (Dianova) were used for negative controls.

In samples with secondary antibodies, anti-CD4 was added after two additional washing procedures; otherwise fluorescein and R-phycocerythrin conjugated antibodies were incubated together.

Instruments were calibrated with beads (Calibrite; Becton-Dickinson) and software (Autocomp; Becton-Dickinson). For gating and calculation, Lysis II software (Becton-Dickinson) was used. Gating for lymphocytes using forward/sideward scatter was facilitated by CD45/CD14 (Becton-Dickinson). For gating and calculation, lymphocytes were segmented in a 3D environment. After 30 min incubation and two washes with PBS, two-colour flow cytometry (FACScan, Becton-Dickinson, Heidelberg, Germany) was performed using the follow-

**Cytokines**

For evaluation of cytokine secretion, AC concentration was adjusted to 10⁶ ACs·mL⁻¹ and cells were cultured unseparated in medium (M199; Gibco, Eggenstein, Germany) supplemented with 5% foetal calf serum (PAA; Linz, Austria) at 37°C in a 5% CO₂ enriched humidified atmosphere for 24 h. Using commercially available enzyme-linked immunosorbent assay (ELISA) kits, IL-1β (PerSeptive Diagnostics, Cambridge, USA), tumour necrosis factor alpha (TNF-α) (PerSeptive Diagnostics), IL-4 (Laboserv, Staufenberg, Germany) and interferon gamma (IFN-γ) (Laboserv) concentrations were measured in the supernatant.
Nonparametric statistical analyses were performed throughout the study. The Mann-Whitney U-test was used for independent samples and correlations were made with the Spearman’s rank correlation test. Values are expressed as mean±SEM. A p-value of less than 0.05 was considered significant.

Results

CR1 and CR2 expression on CD4+ ALs in HIV-1 negative and positive individuals was too low to be reliably detected (1.12±0.21 versus 1.19±0.26 RLMFI and 1.00±0 versus 1.00±0 RLMFI, respectively). Compared to controls, CD4+ ALs from HIV-1 infected individuals showed an increased CR3 and CR4 expression on their surface (15.4±9.10 versus 4.88±5.29 RLMFI (p<0.005) and 12.38±12.66 versus 1.52±1.41 RLMFI, (p<0.005), respectively) (fig. 1). In contrast, a decreased expression of CD46 and CD59 was detected on CD4+ ALs from HIV-1 infected individuals (12.57±11.05 versus 26.68±10.70 RLMFI (p<0.005) and 2.23±0.97 versus 5.83±4.24 RLMFI, respectively (p<0.005)). CD55 was equally expressed on CD4+ ALs in both groups (1.27±0.35 versus 1.15±0.20 RLMFI) (fig. 2).

CD4+ ALs from HIV-1 infected individuals showed an increased expression of CD30 (2.19±1.07 versus 1.25±0.30 RLMFI; p<0.01) (fig. 3). In addition, we found an increased expression of two adhesion molecules that are commonly used as activation parameters on CD4+ ALs from HIV-1 infected individuals (LFA-1 44.27±22.86 versus 25.80±13.03 RLMFI (p<0.05) and ICAM-1 7.74±3.13 versus 2.19±0.98 RLMFI (p<0.005)) (fig. 3).

Besides a decreased expression of CD59 on AMs from HIV-1 infected patients (p<0.05), no significant differences in the expression of any of the above-mentioned epitopes could be detected on AMs (table 1).

<table>
<thead>
<tr>
<th>Complement Receptors</th>
<th>HIV+</th>
<th>HIV-</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR1</td>
<td>1.07±0.59</td>
<td>1.17±0.09</td>
</tr>
<tr>
<td>CR2</td>
<td>1.13±0.29</td>
<td>1.23±0.68</td>
</tr>
<tr>
<td>CR3</td>
<td>8.06±4.77</td>
<td>6.20±3.41</td>
</tr>
<tr>
<td>CR4</td>
<td>5.93±3.46</td>
<td>5.17±2.81</td>
</tr>
<tr>
<td>CD46</td>
<td>5.02±4.18</td>
<td>4.55±2.44</td>
</tr>
<tr>
<td>CD55</td>
<td>1.46±1.08</td>
<td>1.13±0.17</td>
</tr>
<tr>
<td>CD59</td>
<td>1.81±1.04</td>
<td>3.10±2.08</td>
</tr>
<tr>
<td>LFA-1</td>
<td>5.73±4.74</td>
<td>5.09±2.62</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>2.46±0.88</td>
<td>2.04±0.79</td>
</tr>
</tbody>
</table>

Values are presented as mean±sd. AMs were obtained from 17 HIV+ and 12 HIV- subjects (seven volunteers, five patients), RLMFI: relative linear mean fluorescence intensity; HIV: human immunodeficiency virus; + : positive; - : negative; CR: complement receptor; CD: complementary regulatory protein.
The loss of CD46 and CD59 was inversely related to an increased expression of activation markers (LFA-1/CD59: \( r = -0.49, p < 0.005 \); ICAM-1/CD46: \( r = -0.53, p < 0.005 \); ICAM-1/CD59: \( r = -0.55, p < 0.005 \)) and the proposed Th2 marker CD30 (CD30/CD46 \( r = -0.62, p < 0.005 \); CD30/CD59 \( r = -0.61, p < 0.005 \)) (fig. 4).

The concentration of IL-1\( \beta \) (34.44±65.96 pg·mL\(^{-1}\)·10\(^6\) cells\(^{-1}\)) and TNF-\( \alpha \) (411.00±401.29 pg·mL\(^{-1}\)·10\(^6\) cells\(^{-1}\)) in AC supernatants from HIV-1 infected individuals was augmented but showed no correlation to the surface expression (RLMFI) of the tested antigens on ALs or AMs.

IFN-\( \gamma \) concentration was increased in supernatants of ACs from HIV-1 infected individuals (29.23±28.99 versus 10.90±7.58 pg·mL\(^{-1}\)·10\(^6\) cells\(^{-1}\), \( p < 0.05 \)) (fig. 5) and was inversely related to the surface expression CD30 on CD4+ AL within the HIV-1 infected group (n=14, \( r = -0.79, p < 0.005 \)) (fig. 6).

Employing an assay with a lower limit of detection of 7.8 pg·mL\(^{-1}\) we failed to detect the Th2 cytokine IL-4 in supernatants of AC.

Pulmonary infection did not have any demonstrable effect on levels of expression of any of the investigated surface molecules in HIV-1 infected patients (data not shown).

**Discussion**

The broad spectrum of pulmonary diseases seen in HIV-1 infected patients is thought to be a consequence of a virus-induced local immunodeficiency, which is characterized by a severe depletion of CD4+ ALs [9]. Our study was therefore conducted to clarify whether, in HIV-1 infection, expression of complement regulatory and receptor proteins on ACs is altered and contributes to the decline of pulmonary cellular immunity. The main finding of the present study was a significant downregulation of the expression of the complement regulatory proteins CD46 and CD59 on CD4+ AL in HIV-1 infected individuals.

A decreased expression of complement regulatory proteins has been demonstrated on the surface of peripheral blood T-cells from HIV infected patients [8, 11]. In contrast to these reports we found no reduction of CD55 on ALs, which might be due to a low level of expression in HIV-1 negative controls. Unlike previous investigators [8], we detected a reduced expression of complement regulatory proteins, primarily on CD4+ ALs with only a trend toward reduction in the CD4- subset (data not shown). These discrepancies may be attributable to the different investigational sites.

A dysregulation of the expression of complement controlling proteins is known to be of pathogenetic importance in other viral infections, such as measles, where a viral tropism for CD46 on lymphocytes might account for the observed lymphopenia [12]. In HIV-1 infection a loss of complement regulatory proteins is known to facilitate ACC of infected CD4+ T-cells [5] and might render them susceptible for apoptosis [13, 14].
An increased production of TNF-α, CD46, CD55 and CD59 is regulated by cytokines [16]. The following mechanisms may contribute to the down-regulation of membrane-bound complement regulatory proteins in HIV-1 infection.

**Cytokine-mediated regulation**

In human vascular endothelial cells the expression of CD46, CD55 and CD59 is regulated by cytokines [16]. An increased production of TNF-α and IL-1β by blood monocytes [17] and AMs [9, 18] in AIDS patients has been reported. However, we could not establish a correlation between CD46 and CD59 expressed on CD4+ ALs and TNF-α and IL-1β levels. This may be due to the influence of other cytokines, which are known to play a role in the pulmonary immune response to HIV-1 infection. T-cell derived IL-2, for example, has been shown to reconstitute expression of complement regulatory proteins on CD4+ T-cells from HIV-1 infected patients when cultured in vitro [19], which might be one of the mechanisms that account for the rise in CD4+ T-cell counts in some patients treated with intermittent infusions of IL-2 [20].

**Virus-induced effect**

In productively infected CD4+ ALs, HIV-1 itself might cause a reduced expression of complement regulatory proteins. This is due to an incorporation of CD55 and CD59 into newly produced virions protecting them from complement-mediated destruction [21]. However, presuming that the viral load in lung tissue parallels the plasma levels as has been shown for lymph nodes [22], we were not able to establish a correlation between the available plasma HIV-1 ribonucleic acid (RNA) levels (n=13) and the antigen expression on CD4+ AL (data not shown).

**Activation-induced effect**

We found evidence to assume that immune activation is associated with decreased expression of complement regulatory proteins on the surface of CD4+ ALs. The increased expression of LFA-1 and ICAM-1 on CD4+ ALs might be of functional importance since cell adhesion and intercellular communication are essential mechanisms of cellular immunity.

**Th1/Th2 shift**

The expression of CD30 was inversely related to the decline of CD46 and CD59 expression. CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily [23]. CD30 is not exclusively [24], but preferentially [10], expressed on activated CD4+ T-cell clones that produce Th2 cytokines. This finding is supported by the negative correlation we found within the HIV-1 infected cohort between the expression of CD30 on CD4+ ALs and the concentrations of IFN-γ in supernatants of ACs. Unfortunately we were not able to detect IL-4 in supernatants of ACs. This finding is consistent with previous studies reporting high levels of IFN-γ and no detectable IL-4 in supernatants of ALs obtained from HIV-1 infected individuals [25]. A relative predominance of Th2 cells in HIV-1 infection as a consequence of apoptosis and anergy of Th1 cells has recently been postulated [26].

In conclusion, our data indicate that the dysregulation of the expression of cell-bound components of the complement network on CD4+ alveolar lymphocytes from human immunodeficiency virus-1 infected individuals is related to an increased activation of the immune system and a shift in the type 1/type 2 T-helper cell profile. Future studies have to address the functional relevance of these findings for the CD4+ T-cell depletion taking place in the pulmonary compartment.

**Acknowledgements:** The authors thank M. Losch and B. Weitzner for excellent technical assistance and A. Remppis for helpful comments on the text.

**References**


